The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Gene Therapy For Inherited Genetic Disorders Market By 2030 Starting From Its 2026 Size?
The gene therapy for inherited genetic disorders market size has seen significant expansion in recent years. This market is projected to expand from $4.05 billion in 2025 to $4.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 19.3%. The growth observed in the historic period stems from several factors, including the limited availability of advanced gene therapy techniques, reliance on conventional treatments for genetic disorders, an increasing prevalence of inherited genetic diseases, early clinical research on viral vectors, and rising awareness of rare disease management.
The gene therapy for inherited genetic disorders market size is projected to experience substantial expansion over the coming years, reaching $9.69 billion by 2030, driven by a compound annual growth rate (CAGR) of 19.0%. This anticipated growth stems from several factors, including the advancement of novel viral vectors and gene editing technologies, the broader application of RNA-based therapies, the increased uptake of ex vivo stem cell treatments, growing investments in personalized gene therapies, and the enhanced capacity of hospitals and specialty clinics for administering gene therapy. Key trends anticipated during this period encompass the wider deployment of viral vector-based therapies for rare genetic conditions, an increase in ex vivo gene therapy applications, the growing acceptance of RNA-based therapeutics, a heightened emphasis on addressing neurological and ophthalmic disorders, and the incorporation of personalized medicine into gene therapy practices.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp
Which Market Drivers Are Supporting The Expansion Of The Gene Therapy For Inherited Genetic Disorders Market?
The increasing need for personalized medicine is anticipated to drive expansion in the gene therapy for inherited genetic disorders market moving ahead. Personalized medicine involves customizing medical interventions based on a patient’s unique genetic makeup and individual traits to achieve optimal healthcare outcomes. The adoption of personalized medicine is growing, fueled by progress in genetic technologies that facilitate easier and more cost-effective customization of treatments for each person’s distinct genetic composition. This approach enhances gene therapy by adapting treatments to an individual’s specific genetic profile, thereby guaranteeing accurate gene targeting and delivery, boosting efficacy, and minimizing adverse reactions. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the United States Food and Drug Administration (FDA) cleared 16 novel personalized treatments for patients with rare diseases, a significant rise from 6 in 2022. Among the personalized treatments newly sanctioned in 2023 were also seven medications for cancer and three for various other illnesses and conditions. Consequently, the escalating demand for personalized medicine is propelling the expansion of the gene therapy for inherited genetic disorders market.
Which Segment Categories Define The Gene Therapy For Inherited Genetic Disorders Market?
The gene therapy for inherited genetic disorders market covered in this report is segmented –
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy
What Major Market Trends Are Driving Changes In The Gene Therapy For Inherited Genetic Disorders Market?
Companies active in the gene therapy for inherited genetic disorders market are concentrating on developing inventive solutions, such as ex-vivo CRISPR/Cas9-based gene-edited cell therapies, to address the increasing demand for single-application, potentially curative treatments. These therapies aim to lessen lifelong reliance on transfusions, frequent hospitalizations, and substantial chronic-care expenses linked to inherited blood and metabolic disorders. Ex-vivo CRISPR/Cas9 gene-edited cell therapy involves extracting a patient’s hematopoietic stem cells, precisely editing disease-causing genes (or regulatory elements that boost protective fetal hemoglobin) using CRISPR/Cas9, and then reinfusing these modified cells so they engraft and deliver enduring therapeutic benefits. For example, in December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval and achieved commercial availability for CASGEVY (exagamglogene autotemcel). This is a CRISPR/Cas9-based, ex-vivo gene-edited cell therapy designed for sickle cell disease, an inherited genetic disorder. CASGEVY is created from a patient’s own hematopoietic stem cells that are gene edited to increase fetal hemoglobin. The product’s makeup centers on autologous stem cells modified with CRISPR/Cas9; its function is to elevate lasting fetal hemoglobin levels to prevent red-blood-cell sickling; unique attributes include precise genome editing (CRISPR/Cas9) performed ex vivo and a one-time administration with durable effect; its main application is treating severe sickle cell disease (with related indications currently under regulatory review), and the principal benefits observed in trials are considerable reductions in vaso-occlusive crises and transfusion dependence when compared to the prior standard-of-care.
Who Are The Top Companies Competing In The Gene Therapy For Inherited Genetic Disorders Market?
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG
Read the full gene therapy for inherited genetic disorders market report here:
How Is The Gene Therapy For Inherited Genetic Disorders Market Distributed Across Key Geographic Regions?
North America was the largest region in the gene therapy for inherited genetic disorders market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Gene Therapy For Inherited Genetic Disorders Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp
Browse Through More Reports Similar to the Global Gene Therapy For Inherited Genetic Disorders Market 2026, By The Business Research Company
Asphalt Mixing Plants Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-mixing-plants-global-market-report
Asphalt Pavers Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report
Asphalt Additives Market Report 2026
https://www.thebusinessresearchcompany.com/report/asphalt-additives-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model